Background and objective: Inflammation is present to a variable degree and composition in patients with COPD. This study investigates associations between both eosinophils and neutrophils in blood, sputum, airway wall biopsies and bronchoalveolar lavage (BAL) and their potential use as biomarkers for clinical response to inhaled corticosteroids (ICS). Methods: In total, 114 steroid-naïve COPD patients of the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study using ICS or placebo during 30-month follow-up were included. Cell counts in blood, sputum, biopsies and BAL were evaluated at baseline. In addition, at baseline, 6 and 30 months, forced expiratory flow in 1 s (FEV 1 ), residual volume/total lung capacity (hyperinflation) and Clinical COPD Questionnaire were evaluated. Results: Cross-sectional analyses at baseline showed that higher blood eosinophils were significantly associated with higher eosinophil counts in sputum, biopsies and BAL. However, blood neutrophils did not significantly correlate with neutrophil counts in the other compartments. Baseline eosinophils and neutrophils, in whichever compartment measured, did not predict longitudinal FEV 1 changes. Higher baseline biopsy eosinophils were associated with an increase in symptoms during 6-and 30-month ICS treatment. In addition, higher biopsy neutrophils were associated with a more marked reduction in hyperinflation during 6-month ICS treatment compared with placebo. Conclusion: Our findings indicate that blood eosinophils reflect eosinophils in other compartments, in contrast to neutrophils, in ICS-naïve COPD patients. Both
INTRODUCTION
COPD is characterized by incompletely reversible and mainly progressive airflow limitation and respiratory symptoms. 1 Characteristically, inflammation is present in airways and lung tissue in COPD, with neutrophils as distinctive feature. 2 Eosinophilic inflammation is conventionally associated with asthma, but can also be observed in 15-40% of stable COPD patients in sputum, lung tissue and bronchoalveolar lavage (BAL) 3 or even in up to 66% of cases in blood.
A blood eosinophil count of ≥2% in COPD has been suggested as good predictor of sputum eosinophil count >3%. 5 Recent prospective studies showed that COPD patients with ≥2% blood eosinophils have a larger reduction in exacerbation frequency in response to inhaled corticosteroids (ICS) 4, 6 and this group showed a slower decline in forced expiratory volume in 1 s (FEV 1 ) in comparison to placebo. 7 However, it has hardly been investigated whether eosinophils in blood are the best predictor of clinical disease outcome, rather than eosinophils in other bodily compartments more near the site of inflammation in COPD. For instance, eosinophils in airway wall biopsies and BAL have been studied sparsely in relation to clinical disease outcome. In addition, neutrophils are even less studied as biomarker for ICS response, and this is true for all compartments available to measure inflammation in COPD. The Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study 8 showed that ICS reduce FEV 1 decline at least in a subset of COPD patients. However, blood and sputum eosinophils, as well as sputum neutrophils could not predict ICS-induced changes in FEV 1 decline. 9 In asthma, T helper type 2 signature (T2S) high gene expression signature in epithelium is associated with a good FEV 1 response to ICS treatment. 10 In COPD this was not the case, but the same signature predicted a reduction in hyperinflation, measured as residual volume divided by total lung capacity (RV/TLC). 11 Interestingly, this specific T2S-high subgroup of COPD patients also had higher eosinophil counts in airway biopsies, possibly linking eosinophils to hyperinflation.
To obtain better insights in the contribution of inflammatory parameters in different bodily compartments to phenotypes and outcome of COPD, we investigated if inflammatory biomarkers, like eosinophils and neutrophils, in peripheral blood, sputum, airway wall biopsies and BAL are associated with each other. Moreover, we investigated if eosinophils and neutrophils in the four different compartments are related to clinical parameters, such as severity of airflow obstruction, hyperinflation and the Clinical COPD Questionnaire (CCQ), at baseline and their change in time.
METHODS

Study subjects and design
Patient characteristics of the GLUCOLD study have been specified previously. 12 In brief, the included 114 COPD patients were aged between 45-75 years, and current or former smokers with ≥10 pack years. Patients with history of asthma were excluded and patients were not allowed to have used ICS for at least 6 months and oral corticosteroids for at least 3 months prior to the start of the study.
The GLUCOLD study was approved by the local medical ethics committees and all patients provided written informed consent.
The study design has been described previously. 8 In brief, patients randomly received one of the following double-blind, double-dummy treatments: (i) 30-month fluticasone (500 μg b.i.d.); (ii) 30-month fluticasone/ salmeterol (500/50 μg b.i.d.); (iii) 6-month fluticasone (500 μg b.i.d.) followed by 24-month placebo (b.i.d.); or, (iv) 30-month placebo (b.i.d.). We investigated the following measurements at baseline: eosinophils and neutrophils in blood, sputum, airway wall biopsies and BAL, as well as post-bronchodilator FEV 1 , prebronchodilator RV/TLC and CCQ. 13, 14 At 6 and 30 months, the following measurements were repeated: FEV 1 , RV/TLC and CCQ.
Data collection and statistical analysis
Methods for sputum, biopsy and BAL analyses have been described previously 12, 15, 16 (Appendix S1 in Supplementary Information). Due to safety considerations, the BAL procedure was discontinued after 22 months from the onset of the study, as described previously (pleural pain, fever, pneumonia and short-term cardiac ischaemia). 16 Spirometry (post-bronchodilator FEV 1 ) and prebronchodilator body plethysmography (RV/TLC) were assessed using standardized procedures. 12 Health status was measured with CCQ, 13,14 using a scale from 0 to 6 points, higher values indicating lower health status.
Statistical analyses were performed with SPSS Statistics (Version 22.0.0.1 Armonk, NY).
For 6-month analyses, the group receiving 6-month ICS treatment and then switching to placebo was combined with the 30-month ICS AE salmeterol group (Fig. 1) , since adding salmeterol to fluticasone did not affect clinical outcomes of the GLUCOLD study. 8 At 30 months, the ICS AE salmeterol group was analysed separately. Only subjects with >70% treatment compliance were analysed over time by counting the doses on the Discus inhaler.
Clinical characteristics were expressed as mean AE SD, medians (ranges) or n (%). Non-normally distributed variables were normalized by natural logarithmic transformation before analysis. Log-transformed cell counts were expressed as geometric means (CI), Pearson correlations (R p ) were used for crosssectional correlations between inflammatory cells in blood, sputum, biopsies and BAL at baseline. Inflammatory cells in blood, sputum and BAL were expressed as percentages of total cell counts. Inflammatory cells in biopsies were expressed as the natural log transformed number of cells per 0.1 mm 2 of tissue examined.
Cross-sectional univariate linear regression analyses at baseline assessed the relationship between clinical characteristics (dependent variable) and inflammatory cells in blood, sputum, biopsies and BAL (independent variable), corrected for age, gender and smoking.
Longitudinal multivariate linear regression analyses were performed between changes in clinical characteristics over time (dependent variable) and baseline cells in blood, sputum, biopsies and BAL (independent variable), corrected for age, gender and smoking. To investigate if the association between cells at baseline and changes in clinical characteristics differed between treatment groups, we introduced an interaction term between cells and treatment.
RESULTS
Participants
All 114 participants were included in baseline analyses, 101 with treatment compliance in analyses over time. Baseline clinical characteristics were comparable between treatment groups, as were eosinophil and neutrophil counts (Table 1) .
At baseline, blood samples were available in 114 patients, qualified sputum samples in 106 patients, biopsies were performed in 113 patients and BAL in 65 patients. 16 Figure 1 Study design stratified for the different treatment arms in the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study group. Adding salmeterol to the fluticasone arm did not change the clinical outcome of the study, so these two arms are combined for analysis. n, sample size; n adh , number of adherent patients. Cross-sectional correlations between inflammatory cells in blood, sputum, biopsies and BAL at baseline Eosinophils Blood eosinophils showed significant positive correlations with eosinophils in sputum, biopsies and BAL and additionally eosinophils in sputum with eosinophils in biopsies (Table 2) .
Neutrophils
Only neutrophils in sputum and biopsies were significantly and positively correlated biopsies (Table 2) .
Univariate linear associations between inflammatory cells and clinical parameters at baseline Eosinophils
Higher eosinophils in biopsies were significantly associated with lower symptom CCQ scores (n = 111; b = −0.14; P = 0.025). After correction for age, gender and smoking status, there was a trend for an association with symptom CCQ scores (P = 0.06; Table S1 in Supplementary Information).
Neutrophils
There were no significant associations of neutrophils in the four compartments with clinical characteristics (Table S1 in Supplementary Information).
Multivariate linear regression on the association of inflammatory cells at baseline with changes in clinical parameters Eosinophils Eosinophils in whichever compartment measured at baseline were not significantly associated with change in FEV 1 from baseline to 6 months with or without use of ICS (Fig. 2, Table 3 ).
With ICS, higher biopsy eosinophil counts at baseline were significantly associated with greater increases in CCQ scores from baseline to 6 months and to 30 months (Fig. 3) . This effect was not present with placebo; the difference between placebo and ICS was not significantly different.
Higher eosinophil BAL percentages at baseline were significantly associated with larger FEV 1 decreases from baseline to 30-month ICS treatment, without a significant difference between ICS and placebo treatment.
There were no other significant associations between eosinophils in any compartment at baseline and changes in lung function or CCQ scores.
Higher baseline biopsy neutrophil counts were significantly associated with larger increases in RV/TLC up to 6-month with placebo. This effect was not present with ICS treatment. The difference between ICS and placebo was statistically significant (Table S2 in Supplementary  Information) .
The association between neutrophil percentage in BAL at baseline and 30-month change in symptom CCQ score was significantly different between ICS and placebo treatment. Thus, with higher neutrophil percentages in BAL at baseline, ICS treatment was associated with a slight increase in symptoms, whereas placebo was associated with decrease in symptoms.
DISCUSSION
Our study extends previous observations of the GLU-COLD study 9 in 114 ICS-naïve COPD patients and shows that both baseline eosinophils and neutrophils in blood, sputum and biopsies do not predict longitudinal changes in FEV 1 with or without use of ICS. Remarkably, higher biopsy eosinophil counts at baseline predicted a more pronounced longitudinal increase in symptoms with the use of ICS but not with placebo. In addition, higher baseline neutrophil counts in biopsies were significantly associated with a better improvement in hyperinflation after 6-month treatment with ICS versus placebo.
As expected, 5, 17 we found that higher baseline blood eosinophil levels correlate significantly with higher sputum eosinophil levels in COPD. A novel finding is that baseline blood eosinophil levels also significantly correlate with baseline biopsies and BAL eosinophil levels. Although these correlations between eosinophils in blood with the other compartments at baseline were all significant, the percentages of explained variance were not high (ranging from 9 to 32%), implying that prediction of eosinophil counts in sputum, biopsies or BAL based on blood eosinophil levels is unreliable.
Recent studies 4, 6 concluded that ICS treatment in COPD patients with blood eosinophilia does not improve FEV 1 after 1-year follow-up. It could be argued that this is a too short-time window to firmly conclude this. Barnes et al. 7 found in the Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study a reduction of FEV 1 decline over 3 years by ICS in a subgroup with higher blood eosinophils counts at baseline, unfortunately we could not confirm this. The discrepancy between the findings of their study and our results may be explained by the fact that patients in ISOLDE were initially treated with ICS or oral corticosteroids which may have affected baseline eosinophil counts. Thus, the latter study showed that persistent eosinophilia after prednisone treatment predicts a better ICS effect on preventing FEV 1 decline. In contrast, our study shows that blood eosinophilia does not predict a beneficial FEV 1 response to ICS in patients not treated with either prednisone or ICS, which is different from that seen in asthma. 18 We did, however, find an association between higher BAL eosinophil levels at baseline and accelerated FEV 1 decline during 30-month ICS treatment which was not seen during placebo treatment, an interesting finding which we cannot easily explain and needs confirmation in other studies. This is, to our knowledge, the first study investigating associations of eosinophils with hyperinflation in COPD. We did not find a cross-sectional association between eosinophils in any compartment measured and hyperinflation. Eosinophils did also not predict the response of hyperinflation with ICS treatment. This seemingly contrasts to previous results with partly the same groups of patients in GLUCOLD, 11 reporting that a specific T2S gene expression signature in bronchial biopsies was associated with reduction of hyperinflation after ICS treatment. Patients with this T2S gene signature had higher eosinophil counts in bronchial biopsies. It may be worthwhile to use this gene Figure 2 The association between the percentage or number of eosinophils in blood, sputum, biopsies and BAL at baseline and change in ΔFEV 1 %predicted from baseline to 6 months with or without ICS. All associations are not statistically significant (P > 0.05). Eosinophils in biopsies are presented as the natural log transformed (ln) number (n) of cells per 0.1 mm 2 of tissue examined. BAL, bronchoalveolar lavage; ΔFEV 1 , forced expiratory volume in 1 s;
, ICS, inhaled corticosteroids; , placebo.
expression signature in prospective studies instead of eosinophils when analysing treatment effects on hyperinflation.
To our surprise, higher biopsy eosinophils at baseline predict more symptom deterioration during shortand long-term ICS treatment. This finding was not previously reported in the literature, as biopsies are usually not taken in long-term follow-up studies. Moreover, most large cohort studies focussed on exacerbations 19, 20 and did not investigate symptoms with a validated questionnaire. Our finding is difficult to explain and further investigation is clearly needed. Of interest, none of the eosinophil counts of the other compartments associated with symptoms that are relevant to COPD patients as measured in this study. This lack of association of clinical features with eosinophils is different from that seen in asthma. 21, 22 Unexpectedly, and in contrast to eosinophils, neutrophil levels did not correlate well between blood, sputum, biopsies and BAL. Therefore, prediction of neutrophil counts measured in one compartment to another compartment, whichever one, that is blood, sputum, biopsies or BAL, is not reliable.
Our study contrasts to findings of Stanescu et al.
23
who suggest that sputum neutrophilia is associated with accelerated FEV 1 decline. However, in their study neutrophils were only measured at the end, which may have confounded their results; furthermore, effects of ICS were not studied. Our findings now establish that neutrophils measured in blood, sputum, biopsies or BAL in steroid-naïve patients are insensitive biomarkers for short-and long-term ICS response on FEV 1 in COPD. These results are convincing, since our COPD patients were proven to have a beneficial FEV 1 response to ICS with 2.5-year follow-up. 8 In contrast to eosinophils, higher neutrophils in biopsies at baseline were associated with an increase in hyperinflation after 6-month placebo. Of importance, there was a significant difference between effects of placebo and ICS, indicating that without ICS treatment hyperinflation increases. This is in concordance with previous studies 24, 25 showing a decrease of hyperinflation after short-term ICS treatment compared to placebo.
Of interest, none of the neutrophil counts in blood, sputum or biopsies associated with symptoms that are relevant to COPD patients as measured in this study. Higher neutrophil counts in BAL at baseline were associated with a slight increase in symptoms in case of ICS treatment, and a slight decrease in symptoms with placebo. We did not find other studies investigating this, and are curious whether analyses in other studies result in similar findings.
Our study has strengths and limitations. This placebo-controlled trial contains a large group of wellcharacterized COPD patients, with clear exclusion criteria of prior or concomitant history of asthma. By including a placebo group, the natural course of COPD was visible and allowed us to compare this with the effect of ICS treatment. In addition, our study included virtually only steroid-naïve patients so previous beneficial effects of ICS were not present, as well as effects due to quitting ICS in the placebo group, frequently leading to differential drop out of patients. An important feature of our study is the long follow-up, that is for 2.5 years in contrast to 1-year follow-up in previous studies. 4, 6, 26, 27 A drawback of our study is that more males were included than females, which may imperfectly represent the overall COPD population. Secondly, we only analysed longitudinal data from compliant patients and as expected compliance was less in the placebo controlled group. 1 As a result, the effect of the treatment may have been underestimated. Although it would have been of interest to investigate our findings in relation to exacerbations in the GLU-COLD study, we were unable to do this due to lack of power and low number of exacerbations.
In summary, our study shows that higher blood eosinophil levels not only significantly correlate with higher eosinophil levels in sputum, but also in biopsies and BAL, this contrasts to our findings with neutrophils. In addition, we show that eosinophils and neutrophils in blood and sputum are insufficient predictors of short-and long-term ICS response with respect to all our clinical characteristics, that is FEV 1 , hyperinflation, total CCQ and respiratory symptoms. In biopsies, higher neutrophil numbers at baseline were associated with 6-month deterioration in hyperinflation with use of placebo while this was not the case with ICS treatment, indicating prevention of disease progression. The new finding that eosinophils in biopsies were significant predictors of respiratory symptoms during shortand long-term treatment with ICS deserves further investigation.
